No Prescription |
 |
 | ||
|
EBUTOL Myambutol |
|
| ||
No Prescription » Prescription Drugs 6 » EBUTOL Myambutol Ethambutol eliminates certain bacteria that cause tuberculosis (TB). It is used with other medicines to treat tuberculosis and to prevent you from giving the infection to others.Ethambutol comes as a tablet to take by mouth. It usually is taken once a day in the morning. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take ethambutol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Buy EBUTOL Myambutol and other Prescription Drugs 6 products online at Medstore. 490
About EBUTOL Myambutol: Product Type: Prescription Drugs 6 EBUTOL ( Myambutol Generic Ethambutol ) EBUTOL (Myambutol Generic Ethambutol) Myambutol Generic Ethambutol 400mg Tabs 30 ( 3 x 10) Myambutol Generic Ethambutol EBUTOL
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
